Sign Up to like & get
recommendations!
1
Published in 2021 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2021-069
Abstract: Belvarafenib is active in BRAF- and NRAS-mutant tumors, but acquired ARAF mutations drive resistance.
read more here.
Keywords:
mutations limit;
limit response;
raf dimer;
araf mutations ... See more keywords